Disney Has Its Next CEO

Disney announced Josh D'Amaro will succeed Bob Iger as CEO on March 18 with Dana Walden elevated to Chief Creative Officer and Iger remaining an advisor through 2026; streaming has moved from a $2B+ loss in 2022 to roughly $1B in profit, but the stock has been rangebound and management changes raise strategic questions including potential media separations. Chipotle reported Q4 transactions down ~3.2%, revenue up ~5% year-over-year, operating margin slipping to 14.1%, opened 132 restaurants in Q4 and plans up to ~370 new locations in 2026 while forecasting flat comps next year. In pharma, Novo Nordisk warned of a 5–13% decline in 2026 sales/profits amid pricing and patent expiry headwinds for semaglutide, while Eli Lilly posted >40% Q4 revenue growth, expects ~25% revenue growth in 2026 and has become the first pharma to top a $1 trillion market cap, underscoring divergent competitive dynamics in the GLP-1 market.

Analysis

Market structure: GLP-1 disruption is bifurcating winners and losers — Eli Lilly (LLY) and advantaged diversified pharmas gain pricing and market-share tailwinds while Novo Nordisk (NVO) faces near-term 5–13% revenue downside, patent cliffs and margin pressure from generics. In consumer land, parks/experiences (DIS parks) remain the cash engine while fast-casual (CMG) shows structural traffic softness; QSR staples (MCD, DRI, TXRH) should take share as consumers trade down/upscale for occasions.

Risk assessment: Key tail risks are regulatory pricing intervention on GLP-1s (U.S./EU) and accelerated biosimilar entry post-2026 patents, a deeper consumer retrenchment that extends CMG transaction declines beyond four quarters, and management reversals at DIS if Iger remains influential. Time buckets: immediate (days–weeks) = option vol spikes around FDA/earnings; short-term (3–9 months) = GLP-1 competitive dynamics and restaurant comps; long-term (12–36 months) = media/assets spin-offs that can re-rate DIS.

Trade implications: Favor option-levered LLY exposure into expected mid-2026 approvals and hedge NVO with puts; initiate long QSR (MCD/DRI) vs short CMG pair to capture a 15–25% relative spread over 6–12 months. For DIS, size a tactical 2–3% long on <10% pullback and add if management announces asset separations within 12 months; sell covered calls or use verticals to monetize time premium while awaiting corporate action.

Contrarian angles: The market underestimates IP value at Disney — a media/studio carve-out could unlock 20–40% NAV upside over 12–24 months, so transient criticism of leadership may be overdone. Conversely, consensus that GLP-1s are a perpetual gravy train is flawed — pricing erosion and generics will force winners to be scale/portfolio diversified; NVO may be oversold into this re-pricing.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in DIS on any pullback of ≥8–10% from current levels ahead of the March 18 CEO transition; hold 12–24 months and add another 1–2% if management announces a media/studio separation within 12 months.
• Implement a pair trade: short CMG equal-dollar vs long MCD or DRI (pick one) for a target relative outperformance of 15–25% over 6–12 months; initial sizing 1–2% portfolio notional each leg, rebalance if CMG traffic decline extends beyond 4 consecutive quarters.
• Buy a mid-2026 bull call spread on LLY (e.g., Sep–Oct 2026 expiries) sized to 0.5–1% portfolio to capture approval-driven upside while limiting downside; roll or take profits if catalyst occurs by mid-2026.
• Hedge NVO: buy 3–6 month at-the-money puts equal to 1–2% portfolio exposure or establish a small short position (≤1% notional) ahead of FY2026 guidance confirmation, and increase hedge if company reiterates 5–13% downside at next quarterly update.
• If long CMG, protect with 3–6 month put options (cost-budget 1–1.5% portfolio) or sell 3–6 month covered calls to harvest premium while monitoring same-store-sales — trim exposures further if transactions decline another ≥3–5% sequential quarter.